Introduction
When it comes to managing high blood pressure and certain types of heart failure, medications like Valsartan, recognized by its Chemical Abstracts Service (CAS) Number 137862-53-4, play a pivotal role. Valsartan is a widely used angiotensin II receptor blocker (ARB) that helps control hypertension, improve heart function, and reduce the risk of cardiovascular complications. As a pharmaceutical compound, Valsartan has been at the center of both clinical interest and public attention due to its effectiveness and, at times, manufacturing-related controversies.
In this blog, we will explore what Valsartan is, how it works, its benefits, and some considerations associated with its use — all without affiliation to any particular brand or manufacturer.
What is Valsartan (CAS No. 137862-53-4)?
Valsartan is an orally active ARB developed for the treatment of hypertension (high blood pressure), heart failure, and post-myocardial infarction management. It belongs to a class of medications that inhibit the effects of angiotensin II, a hormone that narrows blood vessels and increases blood pressure.
The CAS number 137862-53-4 uniquely identifies this specific chemical compound, ensuring precise communication across scientific, regulatory, and manufacturing contexts. The chemical formula of Valsartan is C24H29N5O3, and it typically appears as a white to off-white crystalline powder.
Mechanism of Action
Valsartan works by selectively blocking the binding of angiotensin II to the AT1 receptor in various tissues such as vascular smooth muscle and the adrenal gland. By preventing this interaction, Valsartan causes vasodilation (widening of blood vessels), reduces secretion of aldosterone (which in turn lowers sodium and water retention), and decreases overall blood pressure.
Unlike ACE inhibitors, which prevent the formation of angiotensin II, ARBs like Valsartan block the receptors that angiotensin II binds to, thereby avoiding some of the common side effects such as persistent cough.
Therapeutic Uses
- Heart Failure
- In patients with heart failure, Valsartan can improve symptoms, reduce hospitalizations, and increase survival by easing the workload on the heart.
- Post-Myocardial Infarction
- After a heart attack, especially when accompanied by left ventricular dysfunction or symptomatic heart failure, Valsartan can help prevent further cardiovascular events.
- Chronic Kidney Disease (Off-label in some regions)
- While not officially approved for this use in all regions, some clinical guidelines suggest ARBs may help slow the progression of kidney disease, particularly in patients with diabetes.
Pharmacokinetics and Dosage
Valsartan is usually administered orally and is available in various strengths. Its bioavailability is approximately 25%, and it reaches peak plasma concentration within 2–4 hours after administration. It is highly protein-bound (~95%) and is primarily excreted unchanged via the bile. The half-life of Valsartan is around 6 hours, although its effects can last longer, allowing for once or twice daily dosing.
Typical starting doses range from 80 mg to 160 mg, depending on the indication and patient profile. Dosages may be adjusted based on therapeutic response and tolerance.
Side Effects and Precautions
Valsartan is generally well tolerated, but like any medication, it can have side effects. Common adverse effects include:
- Dizziness or light-headedness (especially after the first dose)
- Fatigue
- Headache
- Elevated blood potassium levels (hyperkalemia)
More serious but less frequent side effects include kidney dysfunction and hypotension. Valsartan is contraindicated in pregnancy, as it can harm the developing fetus. It is also used cautiously in patients with impaired renal function or those on potassium-sparing diuretics.
Drug Interactions
Patients taking Valsartan should inform their healthcare providers about all medications they are using. Potential interactions include:
- Potassium supplements or salt substitutes (increased risk of hyperkalemia)
- NSAIDs (may reduce the antihypertensive effect and increase risk of kidney damage)
- Other antihypertensives (additive blood pressure-lowering effect)
Regulatory and Safety Considerations
In recent years, there has been global attention surrounding certain batches of Valsartan contaminated with nitrosamine impurities such as NDMA (N-nitrosodimethylamine), which are potential carcinogens. These concerns have prompted recalls and more stringent regulatory oversight to ensure drug purity and patient safety.
However, it’s important to distinguish the compound Valsartan itself from manufacturing issues. When produced in compliance with Good Manufacturing Practices (GMP), Valsartan is a safe and effective medication with decades of clinical experience.
Conclusion
Valsartan (CAS No. 137862-53-4) remains an essential therapeutic agent in the management of hypertension and cardiovascular disease. Its mechanism, safety profile, and efficacy make it a valuable tool for healthcare providers and patients alike. As with any medication, it’s critical to use Valsartan under appropriate medical supervision, considering individual health conditions and potential interactions.
The future of Valsartan, as with many other pharmaceuticals, depends not only on ongoing clinical validation but also on the quality and safety of its manufacturing process. For patients worldwide, access to well-regulated and high-quality medications continues to be a cornerstone of modern healthcare.
URL: For more information, visit Verdant Pharma : CAS NO 137862-53-4 (VALSARTAN)
